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Hedgehog signaling plays a critical role during devel-
opment and tumorigenesis. While much mechanistic
insight has come from pathway investigations in the
fruit fly, recent studies suggest a distinct mammalian
strategy for signaling from Smoothened to Gli through
the novel protein Suppressor of Fused that may have
therapeutic implications.
The challenge of developing therapeutic inhibitors and
activators of major signaling pathways comes when
the targets at which one aims keep moving. This is the
case with the components of the hedgehog (Hh) signal-
ing pathway in mammals. Hh plays a crucial role in de-
velopment and tumorigenesis in metazoan organisms
and promotes proliferation, inhibits differentiation, and
controls migration of stem cells in the body. Inappropri-
ate Hh signaling results in a panoply of developmental
defects and cancers and is implicated in the induction,
maintenance, and/or metastasis of up to 25% of human
tumors (Lum and Beachy, 2004). Intense focus has been
centered around how the Hh signal transduced by the
serpentine receptor Smoothened (Smo) is interpreted
by the Gli/Cubitus interruptus (Ci) zinc finger family of
transcription factors, as this interpretation determines
the magnitude and quality of the resultant Hh-depen-
dent target gene induction. The elegant genetic and cell
biological tools in Drosophila have provided the logic of
the pathway and identified many key components.
However, recent mammalian studies, including two in
this issue of Developmental Cell, reveal critical differ-
ences that have implications for therapeutic targeting.
In both the invertebrate and vertebrate pathways, Hh
ligand binds and inhibits the Patched receptor, allowing
Smo to tip the balance of activity of the Gli/Ci proteins
from repression to activation (Figure 1). Smo does thisin a graded fashion in two ways. First, Smo blocks pro-
tein kinase-dependent Gli3/Ci repressor formation that
occurs through the cleavage of full-length Gli3/Ci into
a smaller transcriptional repressor. Blocking this cleav-
age allows low-level expression of derepressed Hh tar-
get genes. Second, for higher levels of pathway activity,
Smo also enhances the full-length, activator forms of
Gli/Ci. In mammals the main activators are Gli1 and Gli2.
Surprising recent data indicates that mammals have
adopted distinct strategies to control Smo signal trans-
mission to Gli. In flies, the atypical kinesin protein cos-
tal2 (Cos2) is a key interpreter of the signal from Smo.
It does so by scaffolding Ci on vesicles with cleavage-
promoting kinases, thus allowing Ci phosphorylation
and subsequent Ci repressor formation (Zhang et al.,
2005). With the addition of Hh, Smo binds and seques-
ters Cos2 away from the kinases, preventing efficient
Ci repressor formation. Moreover, Cos2 appears to play
an additional role in stimulating activator forms. This is
done by scaffolding the kinase Fused, which acts posi-
tively to increase the transcriptional activity of full-
length Ci (Kalderon, 2004).
By contrast, Varjosalo and colleagues in this issue
show that in mammals Cos2 orthologs KIF7 and KIF27
are not required to regulate Sonic hedgehog (Shh) sig-
naling (Varjosalo et al., 2006). siRNAs that reduce KIF
levels in a variety of cells fail to alter Gli transcription,
suggesting that they no longer serve a function or that
other mammalian kinases can function in their place.
While this study was done in vitro and may not reflect
signaling in the animal, the authors further show that
Smo signaling is also different both in vitro and in trans-
genic animals. Mouse Smo altered in regions corre-
sponding to mutations in fly Smo that disrupt Cos2
binding fail to have identifiable effects on the pathway.
Independent pharmacologic support for a difference
comes from the observation that cyclopamine, a natural
product inhibitor of mammalian Smo, is apparently inac-
tive against fly Smo (Lum and Beachy, 2004). These
three pieces of data, in combination with recent finding
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157Figure 1. Proposed Mechanism of How Smo
Controls the Formation of Repressor and Acti-
vator Forms of Gli/Ci in Drosophila and Mam-
mals
In mammals, components of the primary cilia
such as IFT88 or KIF3a fill an analogous role
as Cos2. Sufu functions are unclear but may
regulate Gli processing or as a corepressor.
Filled black circles are known phosphorylation
events that regulate protein activity, while
open black circles are proposed events.that mouse fused mutations do not exhibit a Hh pheno-
type (Chen et al., 2005), argue that Smo signaling mech-
anisms differ in mammals.
So what takes the place of Cos2? Increasing data
suggest that the primary cilium serve the analogous
function. Primary cilia are small microtubule-based or-
ganelles that use the transport of membrane bound
cargo for signal processing and cellular movement (Cor-
bit et al., 2005; Haycraft et al., 2005). Extensive forward
genetic screens in mice have uncovered a set of mu-
tants resembling Shh mutants (Huangfu and Anderson,
2006), but which contain mutations in components of
the primary cilium. Each mutant has abnormal cilia
and an impaired ability to cleave Gli3 into a repressor,
and fail to stimulate Gli2 into an activator, similar to
theDrosophila cos2 phenotype. Further support for a di-
rect role of the organelle in processing comes from the
colocalization of all three Gli proteins and Smo with
acetylated tubulin, a cilium marker (Corbit et al., 2005;
Haycraft et al., 2005). More experimentation is required
to understand how this small membrane specialization,
either directly or indirectly, controls kinase activity and
Gli processing.
Another big surprise is the key role played by the
novel protein Suppressor of Fused (Sufu). Sufu was
originally identified genetically in Drosophila by its abil-
ity to suppress overactive fused mutations, but is not it-
self required for pathway activity. This has subjected
Sufu to an also-ran role in the pathway for many years.
However, the reports in this issue (Svard et al., 2006;
Varjosalo et al., 2006) and elsewhere (Cooper et al.,
2005) suggest that a key negative regulatory role has
been assumed by Sufu. Sufu null mouse mutants
not only fail to repress the pathway, but have similar
phenotypes as the other key negative regulator actingupstream, patched1. Moreover, Sufu null MEFs and
wild-type cells treated with Sufu siRNAs display maxi-
mal pathway activation, supporting a central role in
pathway repression (Svard et al., 2006; Varjosalo et al.,
2006). Interestingly, in one study the skin phenotype of
Sufu+/2 mice was more severe than that of ptch+/2
mice, as the former spontaneously developed hair folli-
cle tumors (Svard et al., 2006). The result, not seen in the
other studies, could suggest a true divergence in signal-
ing between patched1 and Sufu, or could be due to al-
lele or genetic background differences.
The fact that Sufu plays a critical negative regulatory
role in the pathway is accompanied by a dearth of infor-
mation about how Sufu functions to help transmit Smo
signals to Gli. While the entire Sufu protein is highly con-
served, the lack of recognizable functional domains
makes predicting how and where it acts difficult. Nu-
merous previous reports have demonstrated that Sufu
binds and sequesters Gli1 in the cytoplasm, and one
study shows it works as a transcriptional corepressor
in the nucleus (Huangfu and Anderson, 2006). Recent
data localizing endogenous Sufu in the primary cilium
with Smo and Gli proteins supports the provocative hy-
pothesis that Sufu may also have a role with Smo in Gli
processing in addition to its purported role in the nu-
cleus (Haycraft et al., 2005). Evidence from this issue
argues against a subcellular localization role, as trans-
fected Gli1 remains cytoplasmic in Sufu mutant cells
(Svard et al., 2006). Future studies examining the phos-
phorylation, processing, and activity of the Gli proteins
in Sufu mutants may help better pinpoint Sufu activities.
The emerging mammalian variations of how Smo sig-
nals to Gli are likely to provide a host of new targets for
therapy. Already, Sufu mimetics and antagonists of the
components of the primary cilium appear to be two
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158recent additions. From novel screens to identify path-
way genes, a number of apparently mammalian-specific
regulators may also be added to the list (Huangfu and
Anderson, 2006). In studying their function, one is sure
to find additional surprises and, with luck, additional
useful therapies.
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A Role for Neurotrophins
in Embryonic Stem Cell Growth
Neurotrophins act on embryonic cells through TRK re-
ceptors to inhibit apoptosis by phosphorylation of
AKT. In a recent paper in Nature Biotechnology, Pyle
et al. (2006) show that the presence of selected neuro-
trophins enables cloning of trypsinized single embry-
onic stem cells and potentially increases the availabil-
ity and usefulness of these stem cells.
Human embryonic stem cells (hESCs) are formed from
the inner cell mass (ICM) of developing blastocyst stage
preimplantation embryos (Reubinoff et al., 2000; Thom-
son et al., 1998). hESCs remain undifferentiated when
grown in tightly packed colonies in culture with mouse
embryonic fibroblasts (MEFs) (Reubinoff et al., 2000;
Thomson et al., 1998) or human embryonic fibroblasts
(Amit et al., 2003) and several other cell types. When
overgrown in culture or in the absence of live MEFs,
hESC colonies begin to differentiate, particularly at the
periphery and center of the colony. While MEF-condi-
tioned medium can be used to grow hESCs, it is difficult
to maintain euploidy and survival of undifferentiated
colonies. Passage of hESCs is done weekly or more of-
ten by mechanical division of the colony by using finely
drawn glass needles or scalpel fragments. Trypsiniza-
tion of the colonies and clonal derivation of the hESCs
has also been difficult and is commonly associated
with chromosomal abnormalities, high rates of cell
death, and differentiation (Pera, 2004). These technical
barriers have proved a limitation on hESC studies.
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pathway in the absence of MEF feeders and facilitates
their renewal, clonal derivation, and genetic manipula-
tion. hESCs cannot be maintained by LIF, so it seems
likely that alternative signaling pathway(s) are used for
maintenance and growth of hESCs. A search for cyto-
kines that would enable large-scale, high-throughput
production of hESCs and their clonal derivation has
been a priority for human stem cell biology.
Pyle and colleagues set out to identify factors that
would promote the growth and survival of hESCs. In
their new study, just published in Nature Biotechnology
(Pyle et al., 2006), they describe a role for neurotrophins
in hESC maintenance and renewal. They examined mi-
croarray and SAGE data for evidence of the expression
of cell surface signaling receptors of tyrosine kinases,
and this analysis led to a focus on neurotrophins and
their receptors. Importantly, their discovery has enabled
Pyle et al. to develop a technique that improves the ef-
ficiency of clonal derivation of hESCs. This may well be
a very significant development in embryonic stem cell
biology.
Neurotrophins are a family of growth factors which in-
clude nerve growth factor, brain-derived nerve growth
factor, and neurotrophins (NT) 3 and 4. They act through
binding of their specific receptors: tropomyosin recep-
tor kinases (TRK; consisting of TRKA, TRKB and
TRKC) and p75 neurotrophin receptor (p75NGFR) (re-
viewed in Lu et al., [2005]). Pyle et al. thought the TRK
tyrosine kinase receptors ‘‘might act as receptors for
antiapoptotic factors’’ on hESCs. The lead for this hy-
pothesis is the need to maintain hESCs colonies at
>10 cells to retain their viability during passage on
MEFs or MEF-conditioned medium. Two hESC lines
(HI and H9) tested showed high levels of TRKB and
TRKC expression. TRKB binds BDNF and NT4, while
TRKC binds NT3 (Lu et al., 2005). Importantly, the MEF
